U.S. Women Health Laboratory Testing Market

Industry Overview

The U.S. Women Health Laboratory Testing Market size is expected to reach USD 110.5 billion by 2030 from USD 70.2 billion in 2023, registering a CAGR of 4.5% during the forecast period. The term "U.S. women's health laboratory testing market" refers to the market for testing women's samples in laboratories for conditions like breast cancer, birth control, gynecology disorders, ovarian cancer, and sexually transmitted diseases (STDs) like chlamydia that affect women. The tests that take place throughout prenatal development and those connected to pregnancy are also included. There is an increased number of tests for screening and detection of various diseases so as to avoid complications and enhance the quality of life. Thus, health tests are crucial to improve health and prevent and treat chronic diseases.

Market Segmentation

Insight by Cancer

Based on Cancer, the U.S. Women Health Laboratory Testing Market is segmented into Cervical Cancer, Breast Cancer, and Ovarian Cancer. Breast Cancer is anticipated to grow at a high CAGR during the forecast period owing to rising incidences of breast cancer and increased awareness regarding developed breast cancer diagnostic techniques like ABUS.

Insight by Prenatal Screening and Diagnostic Testing

Based on Prenatal Screening and Diagnostic Testing, the U.S. Women Health Laboratory Testing Market is segregated into Non-Invasive Prenatal Testing (NIPT), Maternal Serum Screening (MSS), Prenatal Diagnostic Testing. Non-Invasive Prenatal Testing (NIPT) dominates the market as it reduces the chances of miscarriage. Owing to increased prominence of trisomy-related genetic conditions, NIPT is expected to grow significantly during the forecasted timeframe.

Insight by Reproductive Health and Infectious Diseases

Based on Reproductive Health and Infectious Diseases, the U.S. Women Health Laboratory Testing Market is divided into Pregnancy and Ovulation Testing, HPV Testing, PAP Smear Testing, HIV Testing, CT/NG Testing, Preimplantation Genetic Testing (PGT), Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia), Herpes Simplex Virus (HSV), Hepatitis, and Vaginal Infections. HIV Testing contributes the largest share in the market owing to the rising number of blood transfusions and blood donations, advantages provided by POC instruments and kits, and rising initiatives by the government that will propel the market development.

U.S. Women Health Laboratory Testing Market Report Coverage

Industry Dynamics

Growth Drivers

Factors attributing to the market growth of U.S. women laboratory testing include mounting prominence of chronic and lifestyle disorders, rising incidences of infectious diseases like HIV, hepatitis, etc., increased awareness among women about health-related tests, increasing average maternal age that has led to high risk of fetal chromosomal aneuploidies. There is also a rise in reproductive health problems, thereby leading to increased market demand for laboratory testing in women. Moreover, the rising geriatric women population, surge in healthcare expenditure, rising incidences of lifestyle diseases in women, established healthcare industry, the surge in demand for fertility tests in women, rising number of private diagnostic and imaging centers, rising population of women in the workforce, and increased public-private partnership will improve infrastructure, thereby bolstering the market growth in the industry.

Challenges

The stringent regulatory guidelines regarding laboratory testing, high cost of diagnostic imaging devices and procedures, shortage of skilled laboratory technicians, and lack of awareness regarding pregnancy and fertility issues in several regions of US will hamper the market development of U.S. women health laboratory testing industry. Moreover, insufficient reimbursements for diagnostic tests will stymie market expansion.

Opportunities

The industry players offer tremendous market opportunities in the U.S. Health Laboratory testing Industry which includes

• Development in diagnostic technologies like genetic testing and digital and mobile mammography like breast MRI, bone density testing, and ultrasound will propel growth.
• Increased number of Regulatory Approvals for Immunoassay diagnostic techniques
• Healthcare Disparities in Rural Counties in the United States
• Healthcare Gap for Reproductive Age in Women with Psychological Distress
• Significant Mergers and Acquisitions by Companies to Increase Market Share

Geographic Overview

• Northeast Region (Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Puerto Rico, Rhode Island, Vermont, Virgin Islands, Virginia and West Virginia)
• Midwest Region (Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin)
• South Region (Alabama, Arkansas, Georgia, Kentucky, Louisiana, Mississippi, Missouri, North Carolina, South Carolina, Tennessee)
• West Region (Alaska, Arizona, California, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming)

South region contributes the largest share in the U.S. women health laboratory testing market owing to increased incidences of lifestyle disorders. The rising implementation of POC and rapid diagnostic testing and an upsurge in the number of diagnostic and imaging centers will support the market advancement of U.S. women health laboratory testing industry.

Competitive Insight

The market for women's health laboratory testing in the United States is in its advanced stages. Partnerships, business expansion, collaborations, product launch, and M&A, as well as increased regulatory, legal, and funding activities, are some of the key strategies adopted by industry players in the U.S. Women Health Laboratory Testing market. Also, New entrants can emphasize in developing early detection tests for hereditary cancer, prenatal screening and diagnostic testing.

Roche Diagnostics offers medical tests and digital tools that provide information to help healthcare professionals find the best treatment for patients and provide the best patient care in order to improve, prolong, and save lives. Roche Diagnostics currently leads the industry in the development of diagnostic products for cancer, cardiovascular health, infectious diseases, women's health, and diabetes management. Roche Diagnostics is the trusted diagnostic partner that healthcare providers can rely on for everything and includes cervical cancer screening, fertility support, prenatal testing, pregnancy care, breast cancer, ovarian cancer diagnosis, and bone health management.

DIASORIN is a prominent leader in laboratory diagnostics, specializing in immunodiagnostics and molecular diagnostics. The Group has been developing, manufacturing, and commercializing diagnostic tests for over 50 years: supports clinical laboratory needs and activities by providing solutions that are reliant, innovative, fully automated, and standardized. DiaSorin strives to invest in Research and development, enhancing its distinct Immunodiagnostics expertise to deliver high-quality assays and increase laboratory efficiency.

Recent Development by Key Players

Myriad Genetics collaborated with Memorial Sloan Kettering Cancer Center to assess the use of minimal residual disease (MRD) testing in patients with breast cancer. The research project will leverage Myriad’s MRD testing platform, a tumour-informed high-definition assay based on whole-genome sequencing, to attain high sensitivity and specificity for circulating tumour DNA (ctDNA).

The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test to aid in the identification of epithelial ovarian cancer (EOC) patients eligible for targeted treatment with ELAHERETM (mirvetuximab soravtansine-gynx), has been approved by the US Food and Drug Administration (FDA). ELAHERE is a first-in-class antibody-drug conjugate (ADC) therapy approved by the FDA under the Accelerated Approval program for the treatment of FR-positive platinum-resistant ovarian cancer.

Quest Diagnostics, the world's leading provider of diagnostic information services, and Northern Light Health, a large integrated healthcare system in Maine, announced a strategic laboratory collaboration to expand access to innovative, high-quality, and cost-effective laboratory services, enabling communities in Maine to receive affordable care.

Key Players Covered in the Report

Some of the key players operating in the U.S. Women Health Diagnostics Industry include F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., DiaSorin S.p.A, Natera, Inc., Becton, Dickinson and Company, Hologic, Inc., Quest Diagnostics Incorporated, Abbott, Cardinal Health, and GE HealthCare.

The U.S. Women Health Laboratory Testing Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2025–2030.

Segments Covered in the Report

• By Cancer
  • Cervical Cancer
  • Breast Cancer
  • Ovarian Cancer
• By Prenatal Screening and Diagnostic Testing
  • Non-Invasive Prenatal Testing (NIPT)
  • Maternal Serum Screening (MSS)
  • Prenatal Diagnostic Testing
• By Reproductive Health and Infectious Diseases
  • Pregnancy and Ovulation Testing
  • HPV Testing
  • PAP Smear Testing
  • HIV Testing
  • CT/NG Testing
  • Preimplantation Genetic Testing (PGT)
  • Sexually Transmitted Infections
  • Herpes Simplex Virus (HSV)
  • Hepatitis
  • Vaginal Infections

To explore more about this report - Request a free sample copy

1.    Research Overview

        1.1.    The Report Offers
        1.2.    Market Coverage
                1.2.1.    By Cancer
                1.2.2.    By Prenatal Screening and Diagnostic Testing
                1.2.3.    By Reproductive Health and Infectious Diseases
                1.2.4.    By Region
        1.3.    Research Phases
        1.4.    Limitations
        1.5.    Market Methodology
                1.5.1.    Data Sources
                        1.5.1.1. Primary Research
                        1.5.1.2. Secondary Research
                1.5.2.    Methodology
                        1.5.2.1. Data Exploration
                        1.5.2.2. Forecast Parameters
                        1.5.2.3. Data Validation
                        1.5.2.4. Assumptions
                1.5.3.    Study Period & Data Reporting Unit

2.    Executive Summary

3.    Industry Overview

        3.1.    Industry Dynamics
                3.1.1.    Market Growth Drivers
                3.1.2.    Market Restraints
                3.1.3.    Key Market Trends
                3.1.4.    Major Opportunities
        3.2.    Industry Ecosystem
                3.2.1.    Porter’s Five Forces Analysis
                3.2.2.    Recent Development Analysis
                3.2.3.    Value Chain Analysis
        3.3.    Competitive Insight
                3.3.1.    Competitive Position of Industry Players
                3.3.2.    Market Attractive Analysis
                3.3.3.    Market Share Analysis

4.    Global Market Estimate and Forecast

        4.1.    Global Market Overview
        4.2.    Global Market Estimate and Forecast to 2030

5.    Market Segmentation Estimate and Forecast

        5.1.    By Cancer
                5.1.1.    Cervical Cancer
                        5.1.1.1. Market Definition
                        5.1.1.2. Market Estimation and Forecast to 2030 
                5.1.2.    Breast Cancer
                        5.1.2.1. Market Definition
                        5.1.2.2. Market Estimation and Forecast to 2030
                5.1.3.    Ovarian Cancer
                        5.1.3.1. Market Definition
                        5.1.3.2. Market Estimation and Forecast to 2030
                
        5.2.    By Prenatal Screening and Diagnostic Testing
                5.2.1.    Non-Invasive Prenatal Testing (NIPT)
                        5.2.1.1. Market Definition
                        5.2.1.2. Market Estimation and Forecast to 2030
                5.2.2.    Maternal Serum Screening (MSS)
                        5.2.2.1. Market Definition
                        5.2.2.2. Market Estimation and Forecast to 2030
                5.2.3.    Prenatal Diagnostic Testing
                        5.2.3.1. Market Definition
                        5.2.3.2. Market Estimation and Forecast to 2030

        5.3.    By Reproductive Health and Infectious Diseases
                5.3.1.    Pregnancy and Ovulation Testing
                        5.3.1.1. Market Definition
                        5.3.1.2. Market Estimation and Forecast to 2030
                5.3.2.    HPV Testing
                        5.3.2.1. Market Definition
                        5.3.2.2. Market Estimation and Forecast to 2030
                5.3.3.    PAP Smear Testing
                        5.3.3.1. Market Definition
                        5.3.3.2. Market Estimation and Forecast to 2030
                5.3.4.    HIV Testing
                        5.3.4.1. Market Definition
                        5.3.4.2. Market Estimation and Forecast to 2030
                5.3.5.    CT/NG Testing
                        5.3.5.1. Market Definition
                        5.3.5.2. Market Estimation and Forecast to 2030
                5.3.6.    Preimplantation Genetic Testing (PGT)
                        5.3.6.1. Market Definition
                        5.3.6.2. Market Estimation and Forecast to 2030
                5.3.7.    Sexually Transmitted Infections
                        5.3.7.1. Market Definition
                        5.3.7.2. Market Estimation and Forecast to 2030
                5.3.8.    Herpes Simplex Virus (HSV)
                        5.3.8.1. Market Definition
                        5.3.8.2. Market Estimation and Forecast to 2030
                5.3.9.    Hepatitis
                        5.3.9.1. Market Definition
                        5.3.9.2. Market Estimation and Forecast to 2030
                5.3.10.    Vaginal Infections
                        5.3.10.1. Market Definition
                        5.3.10.2. Market Estimation and Forecast to 2030
                                                   
6.    Northeast Market Estimate and Forecast

        6.1.    By Cancer
        6.2.    By Prenatal Screening and Diagnostic Testing
        6.3.    By Reproductive Health and Infectious Diseases
        6.4.    By Country
                6.4.1.    Connecticut Market Estimate and Forecast
                6.4.2.    Delaware Market Estimate and Forecast
                6.4.3.    District of Columbia Market Estimate and Forecast
                6.4.4.    Maine Market Estimate and Forecast
                6.4.5.    New York Market Estimate and Forecast
                6.4.6.    Massachusetts Market Estimate and Forecast
                6.4.7.    New Jersey Market Estimate and Forecast
                6.4.8.    Rest of Northeast Market Estimate and Forecast

7.    Midwest Market Estimate and Forecast

        7.1.    By Cancer
        7.2.    By Prenatal Screening and Diagnostic Testing
        7.3.    By Reproductive Health and Infectious Diseases
        7.4.    By Country
                7.4.1.    Illinois Market Estimate and Forecast
                7.4.2.    Ohio Market Estimate and Forecast
                7.4.3.    Indiana Market Estimate and Forecast
                7.4.4.    Michigan Market Estimate and Forecast
                7.4.5.    Missouri Market Estimate and Forecast
                7.4.6.    Rest of Midwest Market Estimate and Forecast

8.    South Market Estimate and Forecast

        8.1.    By Cancer
        8.2.    By Prenatal Screening and Diagnostic Testing
        8.3.    By Reproductive Health and Infectious Diseases
        8.4.    By Country
                8.4.1.    Alabama Market Estimate and Forecast
                8.4.2.    Mississippi Market Estimate and Forecast
                8.4.3.    Georgia Market Estimate and Forecast
                8.4.4.    Louisiana Market Estimate and Forecast
                8.4.5.    Arkansas Market Estimate and Forecast
                8.4.6.    Rest of South Market Estimate and Forecast

9.    West Market Estimate and Forecast

        9.1.    By Cancer
        9.2.    By Prenatal Screening and Diagnostic Testing
        9.3.    By Reproductive Health and Infectious Diseases
        9.4.    By Country
                9.4.1.    Alaska Market Estimate and Forecast
                9.4.2.    California Market Estimate and Forecast
                9.4.3.    Washington Market Estimate and Forecast
                9.4.4.    Other Countries Market Estimate and Forecast

10.    Company Profiles

        10.1.     F. Hoffmann-La Roche Ltd
                10.1.1.    Snapshot
                10.1.2.    Overview
                10.1.3.    Offerings
                10.1.4.    Financial Insight
                10.1.5.    Recent Developments
        10.2.     Myriad Genetics, Inc.
                10.2.1.    Snapshot
                10.2.2.    Overview
                10.2.3.    Offerings
                10.2.4.    Financial Insight
                10.2.5.    Recent Developments
        10.3. DiaSorin S.p.A
                10.3.1.    Snapshot
                10.3.2.    Overview
                10.3.3.    Offerings
                10.3.4.    Financial Insight
                10.3.5.    Recent Developments
        10.4.    Natera, Inc.
                10.4.1.    Snapshot
                10.4.2.    Overview
                10.4.3.    Offerings
                10.4.4.    Financial Insight
                10.4.5.    Recent Developments
        10.5. Becton, Dickinson and Company
                10.5.1.    Snapshot
                10.5.2.    Overview
                10.5.3.    Offerings
                10.5.4.    Financial Insight
                10.5.5.    Recent Developments
        10.6. Hologic, Inc.
                10.6.1.    Snapshot
                10.6.2.    Overview
                10.6.3.    Offerings
                10.6.4.    Financial Insight
                10.6.5.    Recent Developments
        10.7.    Quest Diagnostics Incorporated
                10.7.1.    Snapshot
                10.7.2.    Overview
                10.7.3.    Offerings
                10.7.4.    Financial Insight
                10.7.5.    Recent Developments
        10.8.    Abbott
                10.8.1.    Snapshot
                10.8.2.    Overview
                10.8.3.    Offerings
                10.8.4.    Financial Insight
                10.8.5.    Recent Developments
        10.9.    Cardinal Health
                10.9.1.    Snapshot
                10.9.2.    Overview
                10.9.3.    Offerings
                10.9.4.    Financial Insight
                10.9.5.    Recent Developments
        10.10. GE HealthCare
                10.10.1. Snapshot
                10.10.2. Overview
                10.10.3. Offerings
                10.10.4. Financial Insight
                10.10.5. Recent Developments

11.    Appendix

        11.1.    Exchange Rates
        11.2.    Abbreviations

Note: Financial insight and recent developments of different companies are subject to availability of information in secondary domain.

List of Tables

Table 1 Sources
Table 2 Study Periods
Table 3 Data Reporting Unit
Table 4 U.S. Women Health Laboratory Testing Market Size, By Cancer, 2018-2023 (USD Billion)
Table 5 U.S. Women Health Laboratory Testing Market Size, By Cancer, 2025-2030 (USD Billion)
Table 6 U.S. Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2018-2023 (USD Billion)
Table 7 U.S. Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2025-2030 (USD Billion)
Table 8 U.S. Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2018-2023 (USD Billion)
Table 9 U.S. Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2025-2030 (USD Billion)
Table 10 U.S. Women Health Laboratory Testing Market Size, by Region, 2018-2023 (USD Billion)
Table 11 U.S. Women Health Laboratory Testing Market Size, by Region, 2025-2030 (USD Billion)
Table 12 Northeast Women Health Laboratory Testing Market Size, By Cancer, 2018-2023 (USD Billion)
Table 13 Northeast Women Health Laboratory Testing Market Size, By Cancer, 2025-2030 (USD Billion)
Table 14 Northeast Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2018-2023 (USD Billion)
Table 15 Northeast Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2025-2030 (USD Billion)
Table 16 Northeast Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2018-2023 (USD Billion)
Table 17 Northeast Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2025-2030 (USD Billion)
Table 18 Northeast Women Health Laboratory Testing Market Size, by Region, 2018-2023 (USD Billion)
Table 19 Northeast Women Health Laboratory Testing Market Size, by Region, 2025-2030 (USD Billion)
Table 20 Midwest Women Health Laboratory Testing Market Size, By Cancer, 2018-2023 (USD Billion)
Table 21 Midwest Women Health Laboratory Testing Market Size, By Cancer, 2025-2030 (USD Billion)
Table 22 Midwest Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2018-2023 (USD Billion)
Table 23 Midwest Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2025-2030 (USD Billion)
Table 24 Midwest Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2018-2023 (USD Billion)
Table 25 Midwest Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2025-2030 (USD Billion)
Table 26 Midwest Women Health Laboratory Testing Market Size, by Region, 2018-2023 (USD Billion)
Table 27 Midwest Women Health Laboratory Testing Market Size, by Region, 2025-2030 (USD Billion)
Table 28 South Women Health Laboratory Testing Market Size, By Cancer, 2018-2023 (USD Billion)
Table 29 South Women Health Laboratory Testing Market Size, By Cancer, 2025-2030 (USD Billion)
Table 30 South Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2018-2023 (USD Billion)
Table 31 South Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2025-2030 (USD Billion)
Table 32 South Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2018-2023 (USD Billion)
Table 33 South Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2025-2030 (USD Billion)
Table 34 South Women Health Laboratory Testing Market Size, by Region, 2018-2023 (USD Billion)
Table 35 South Women Health Laboratory Testing Market Size, by Region, 2025-2030 (USD Billion)
Table 36 West Women Health Laboratory Testing Market Size, By Cancer, 2018-2023 (USD Billion)
Table 37 West Women Health Laboratory Testing Market Size, By Cancer, 2025-2030 (USD Billion)
Table 38 West Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2018-2023 (USD Billion)
Table 39 West Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2025-2030 (USD Billion)
Table 40 West Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2018-2023 (USD Billion)
Table 41 West Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2025-2030 (USD Billion)
Table 42 West Women Health Laboratory Testing Market Size, by Region, 2018-2023 (USD Billion)
Table 43 West Women Health Laboratory Testing Market Size, by Region, 2025-2030 (USD Billion)
Table 44 Snapshot – F. Hoffmann-La Roche Ltd
Table 45 Snapshot – Myriad Genetics, Inc.
Table 46 Snapshot – DiaSorin S.p.A
Table 47 Snapshot – Natera, Inc.
Table 48 Snapshot – Becton, Dickinson and Company
Table 49 Snapshot – Hologic, Inc.
Table 50 Snapshot – Quest Diagnostics Incorporated
Table 51 Snapshot – Abbott
Table 52 Snapshot – Cardinal Health
Table 53 Snapshot – GE HealthCare

List of Figures

Figure 1 Market Coverage
Figure 2 Research Phases
Figure 3 Secondary Sources for Different Parameters
Figure 4 Methodology
Figure 5 Data Mining & Exploration
Figure 6 Data Triangulation
Figure 7 Assumptions for Market Estimation and Forecast
Figure 8 Market Synopsis
Figure 9 U.S. Women Health Laboratory Testing Market - Growth Drivers and Restraints
Figure 10 Competitive Benchmark
Figure 11 U.S. Women Health Laboratory Testing Market Highlight
Figure 12 U.S. Women Health Laboratory Testing Market Size, By Cancer, 2018-2021 (USD Billion)
Figure 13 U.S. Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2018-2021 (USD Billion)
Figure 14 U.S. Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2018-2021 (USD Billion)
Figure 15 U.S. Women Health Laboratory Testing Market Size, by Region, 2018-2021 (USD Billion)
Figure 16 Northeast Women Health Laboratory Testing Market Highlight
Figure 17 Northeast Women Health Laboratory Testing Market Size, By Cancer, 2018 - 2030 (USD Billion)
Figure 18 Northeast Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2018 - 2030 (USD Billion)
Figure 19 Northeast Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2018 - 2030 (USD Billion)
Figure 20 Northeast Women Health Laboratory Testing Market Size, by Region, 2018 - 2030 (USD Billion)
Figure 21 Midwest Women Health Laboratory Testing Market Highlight
Figure 22 Midwest Women Health Laboratory Testing Market Size, By Cancer, 2018 - 2030 (USD Billion)
Figure 23 Midwest Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2018 - 2030 (USD Billion)
Figure 24 Midwest Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2018 - 2030 (USD Billion)
Figure 25 Midwest Women Health Laboratory Testing Market Size, by Region, 2018 - 2030 (USD Billion)
Figure 26 South Women Health Laboratory Testing Market Highlight
Figure 27 South Women Health Laboratory Testing Market Size, By Cancer, 2018 - 2030 (USD Billion)
Figure 28 South Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2018 - 2030 (USD Billion)
Figure 29 South Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2018 - 2030 (USD Billion)
Figure 30 South Women Health Laboratory Testing Market Size, by Region, 2018 - 2030 (USD Billion)
Figure 31 West Women Health Laboratory Testing Market Highlight
Figure 32 West Women Health Laboratory Testing Market Size, By Cancer, 2018 - 2030 (USD Billion)
Figure 33 West Women Health Laboratory Testing Market Size, By Prenatal Screening and Diagnostic Testing, 2018 - 2030 (USD Billion)
Figure 34 West Women Health Laboratory Testing Market Size, By Reproductive Health and Infectious Diseases, 2018 - 2030 (USD Billion)
Figure 35 West Women Health Laboratory Testing Market Size, by Region, 2018 - 2030 (USD Billion)